Drug Trial Radar · NCT04381468
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jul 22, 2021
Primary completion
Jun 5, 2024
Study completion Jun 5, 2024
Sponsor
- Lead sponsor
- Vaccinex Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Alzheimer's Drug Discovery Foundation; Alzheimer's Association
- First posted
- May 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Conditions
- Alzheimer Disease
Interventions
PepinemabDrug
Pepinemab is a humanized IgG4 monoclonal antibody. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
PlaceboDrug
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with treatment emergent adverse events (TEAEs)Time frame: Up to 40 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Pacific Research Network, Inc
San Diego, California
Georgetown University
Washington D.C., District of Columbia
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
JEM Research Institute
Lake Worth, Florida
Premiere Research Institute of Palm Beach, Neurology
Palm Beach, Florida
Brain Matters Research
Stuart, Florida
Indiana University School of Medicine
Indianapolis, Indiana
University of Kansas Medical Center
Fairway, Kansas
Neurological Associates of Albany
Albany, New York
Dent Neurological Associates
Amherst, New York
Columbia University Irving Medical Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Re-Cognition Health
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.